Key facts
- CustoMED’s last known valuation is $7.1M (Oct 2025).
- It has raised $6.0M; the latest was Accelerator/Incubator in Apr 2026.
- Notable investors include Innovation Authority, ARC Innovation Center, Avishai Abrahami, Flag Capital, Longevity Venture Partners — 6 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 6 names
- ·Watchlist + deal alerts for CustoMED
- ·The full record, as it builds
Funding rounds
No funding rounds for CustoMED are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About CustoMED
Developer of surgical planning and personalised implant software designed to enable on-site creation of patient-specific medical devices. The company's platform converts medical imaging into interactive anatomical models, supports automated segmentation, surgical planning, and generation of patient-specific instruments for local printing, enabling surgeons and healthcare providers to improve surgical precision, reduce procedure time, and deliver customized treatments efficiently.
- Sector
- Healthcare
- HQ
- Ramat Gan, Israel
- Founded
- 2023
- Employees
- 17
- Website
- customed.ai/
- Ownership
- Privately Held (backing)
CustoMED doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in CustoMED shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on CustoMED in its N-PORT filings yet. We sweep new filings monthly.